Core Insights - Firefly Neuroscience Inc. is experiencing a significant increase in its stock price due to advancements in brain scan technologies and a notable expansion in its commercial operations [1] Group 1: Commercial Expansion - Firefly reported a 20-fold expansion of its commercial footprint and a 33-fold increase in EEG/ERP brain scan volumes [2] - The company ended 2025 with partnerships with 99 commercial users, completing over 10,800 EEG/ERP brain scans, reflecting year-over-year increases of 1,880% in partner sites and 3,227% in clinical assessments [2] - Firefly's proprietary database now contains over 191,000 EEG/ERP brain scans, making it the largest known standardized EEG/ERP repository [3] Group 2: Stock Performance - The stock is currently trading 103.6% above its 20-day simple moving average (SMA) and 18.1% above its 100-day SMA, indicating short-term strength [4] - Over the past 12 months, shares have decreased by 63.40%, and they are closer to their 52-week lows than highs [4] - Firefly Neuroscience shares were up 15.49% at $1.64, with key resistance at $2.00 and key support at $1.00 [6] Group 3: Technical Indicators - The RSI is at 72.82, indicating that the stock is in overbought territory, which may suggest a potential pullback [5] - The MACD is at 0.0411, above its signal line at -0.0517, indicating bullish momentum [5] - The combination of overbought RSI and bullish MACD suggests mixed momentum, indicating current strength but caution may be warranted due to the overbought condition [5]